Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 6, 2009, Pages 635-643

  Ho, M K ^a   Mwenifumbo, J C ^a   Al Koudsi, N ^a   Okuyemi, K S ^b   Ahluwalia, J S ^b   Benowitz, N L ^c   Tyndale, R F ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; NICOTINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CIGARETTE SMOKING; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; MOLECULAR PHYLOGENY; PHENOTYPE; PRIORITY JOURNAL; SMOKING CESSATION;

ADULT; AFRICAN AMERICANS; AGED; ARYL HYDROCARBON HYDROXYLASES; BODY MASS INDEX; COTININE; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NICOTINE; POLYMORPHISM, GENETIC; SMOKING CESSATION;

EID: 67349284846     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.19     Document Type: Article

References (48)

1. Kandel, D.B. & Chen, K. Extent of smoking and nicotine dependence in the United States: 1991-1993. Nicotine Tob. Res. 2, 263-274 (2000).
2. Royce, J.M., Hymowitz, N., Corbett, K., Hartwell, T.D. & Orlandi, M.A. Smoking cessation factors among African Americans and whites. COMMIT Research Group. Am. J. Public Health 83, 220-226 (1993).
3. Centers for Disease Control and Prevention (CDC).Smoking cessation during previous year among adults-United States, 1990 and 1991. MMWR Morb. Mortal. Wkly. Rep. 42, 504-507 (1993).
4. Centers for Disease Control and Prevention. Tobacco use among U.S. racial/ ethnic minority groups-African-Americans, American-Indians and Alaska Natives, Asian-Americans and Pacifc Islanders, and Hispanics: a report of the Surgeon General (Department of Health and Human Services, Atlanta, GA, 1998).
5. Haiman, C.A. et al. Ethnic and racial diferences in the smoking-related risk of lung cancer. N. Engl. J. Med. 354, 333-342 (2006).
6. US Department of Health and Human Services. Tobacco use among U.S. racial/ethnic minority groups: African Americans, American Indians and Alaska Natives, Asian Americans and Pacifc Islanders, Hispanics: A report of the Surgeon General, 1998. Government Printing Ofce publication no. S/N 017-001-00527-4 (Centers for Disease Control and Prevention: Office on Smoking and Health, Atlanta, GA, 1998).
7. Clark, P.I., Gautam, S. & Gerson, L.W. Efect of menthol cigarettes on biochemical markers of smoke exposure among black and white smokers. Chest 110, 1194-1198 (1996).
8. Benowitz, N.L., Perez-Stable, E.J., Fong, I., Modin, G., Herrera, B. & Jacob, P. 3rd. Ethnic diferences in N-glucuronidation of nicotine and cotinine. J. Pharmacol. Exp. Ther. 291, 1196-1203 (1999).
9. Muscat, J.E., Djordjevic, M.V., Colosimo, S., Stellman, S.D. & Richie, J.P. Jr. Racial diferences in exposure and glucuronidation of the tobacco-specifc carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Cancer 103, 1420-1426 (2005).
10. Benowitz, N.L. Nicotine addiction. Prim. Care 26, 611-631 (1999).
11. Benowitz, N.L. & Jacob, P. 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56, 483-493 (1994).
12. Messina, E.S., Tyndale, R.F. & Sellers, E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282, 1608-1614 (1997).
13. Nakajima, M. et al. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277, 1010-1015 (1996).
14. Dempsey, D. et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76, 64-72 (2004).
15. Yamazaki, H., Inui, Y., Yun, C.H., Guengerich, F.P. & Shimada, T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13, 1789-1794 (1992).
16. Mwenifumbo, J.C. & Tyndale, R.F. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 8, 1385-1402 (2007).
17. Higashi, E. et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab. Dispos. 35, 1935-1941 (2007).
18. Benowitz, N.L., Lessov-Schlaggar, C.N., Swan, G.E. & Jacob, P. 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79, 480-488 (2006).
19. McMorrow, M.J. & Foxx, R.M. Nicotine's role in smoking: an analysis of nicotine regulation. Psychol. Bull. 93, 302-327 (1983).
20. Benowitz, N.L., Swan, G.E., Jacob, P. 3rd, Lessov-Schlaggar, C.N. & Tyndale, R.F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther. 80, 457-467 (2006).
21. Rao, Y. et al. Duplications and defects in the CYP2A6 gene: identifcation, genotyping, and in vivo efects on smoking. Mol. Pharmacol. 58, 747-755 (2000).
22. Mwenifumbo, J.C. et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum. Mutat. 29, 679-688 (2008).
23. Schoedel, K.A., Hofmann, E.B., Rao, Y., Sellers, E.M. & Tyndale, R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14, 615-626 (2004).
24. Strasser, A.A., Malaiyandi, V., Hofmann, E., Tyndale, R.F. & Lerman, C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob. Res. 9, 511-518 (2007).
25. Kubota, T. et al. CYP2A6 polymorphisms are associated with nicotine dependence and infuence withdrawal symptoms in smoking cessation. Pharmacogenomics J. 6, 115-119 (2006).
26. Patterson, F. et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther. 84, 320-325 (2008).
27. Lerman, C. et al. Nicotine metabolite ratio predicts efcacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79, 600-608 (2006).
28. Schnoll, R.A., Patterson, F., Wileyto, E.P., Tyndale, R.F., Benowitz, N. & Lerman, C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol. Biochem. Behav. 92, 6-11 (2009).
29. Gu, D.F., Hinks, L.J., Morton, N.E. & Day, I.N. The use of long PCR to confrm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann. Hum. Genet. 64, 383-390 (2000).
30. Malaiyandi, V., Goodz, S., Sellers, E.M. & Tyndale, R.F. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol. Biomarkers Prev. 15, 1812-1819 (2006).
31. Johnstone, E. et al. Determinants of the rate of nicotine metabolism and efects on smoking behavior. Clin. Pharmacol. Ther. 80, 319-330 (2006).
32. Ahluwalia, J.S. et al. The efects of nicotine gum and counseling among African American light smokers: a 2×2 factorial design. Addiction 101, 883-891 (2006).
33. Mwenifumbo, J.C. et al. Identifcation of novel CYP2A6[ast]1B variants: the CYP2A6[ast]1B allele is associated with faster in vivo nicotine metabolism. Clin. Pharmacol. Ther. 83, 115-121 (2007).
34. Fukami, T., Nakajima, M., Yamanaka, H., Fukushima, Y., McLeod, H.L. & Yokoi, T. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab. Dispos. 35, 515-520 (2007).
35. Ho, M.K., Mwenifumbo, J.C., Zhao, B., Gillam, E.M. & Tyndale, R.F. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black African descent. Pharmacogenetics Genomics 18, 67-75 (2008).
36. Etter, J.F., Le Houezec, J. & Perneger, T.V. A self-administered questionnaire to measure dependence on cigarettes: the cigarette dependence scale. Neuropsychopharmacology 28, 359-370 (2003).
37. Heatherton, T.F., Kozlowski, L.T., Frecker, R.C. & Fagerström, K.O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 86, 1119-1127 (1991).
38. Nollen, N.L. et al. Predictors of quitting among African American light smokers enrolled in a randomized, placebo-controlled trial. J. Gen. Intern. Med. 21, 590-595 (2006).
39. Lea, R.A., Dickson, S. & Benowitz, N.L. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J. Anal. Toxicol. 30, 386-389 (2006).
40. Mooney, M.E., Li, Z.Z., Murphy, S.E., Pentel, P.R., Le, C. & Hatsukami, D.K. Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol. Biomarkers Prev. 17, 1396-1400 (2008).
41. Mwenifumbo, J.C., Sellers, E.M. & Tyndale, R.F. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend. 89, 24-33 (2007).
42. Swan, G.E., Lessov-Schlaggar, C.N., Bergen, A.W., He, Y., Tyndale, R.F. & Benowitz, N.L. Genetic and environmental infuences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine. Pharmacogenetics Genomics (in press).
43. Benowitz, N.L., Herrera, B. & Jacob, P. 3rd. Mentholated cigarette smoking inhibits nicotine metabolism. J. Pharmacol. Exp. Ther. 310, 1208-1215 (2004).
44. Scherer, G. Smoking behavior and compensation: a review of the literature. Psychopharmacology 145, 1-20 (1999).
45. Shifman, S. & Paty, J. Smoking patterns and dependence: contrasting chippers and heavy smokers. J. Abnorm. Psychol. 115, 509-523 (2006).
46. Piper, M.E. et al. Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Nicotine Tob. Res. 10, 1009-1020 (2008).
47. Ofce of Applied Studies, Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health: past month cigarette use among racial and ethnic groups. (2006).
48. Goodz, S.D. & Tyndale, R.F. Genotyping human CYP2A6 variants. Methods Enzymol. 357, 59-69 (2002).